Insulin dysregulation and hyperinsulinemia is a horse welfare problem that also increase the incidence of the severely painful condition laminitis in horses. Today, no pharmacological treatment is available but recent weak evidence suggest that Sodium-glucose cotransporters (SGLT) inhibitors (e.g. canagliflozin) have the potential to prevent laminitis and improve horse welfare. There is no information available about the uptake, distribution, elimination or safety of canagliflozin in horses. This project aims at investigating the pharmacokinetics, pharmacodynamics and the safety of canagliflozin in order to establish clinical dose recommendations.